$405.2 M

NITE Mkt cap, 11-Oct-2018
Nightstar Therapeutics Net income (H1, 2017)-7.7 M
Nightstar Therapeutics EBIT (H1, 2017)-7.7 M
Nightstar Therapeutics Cash, 30-Jun-201769.6 M

Nightstar Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016

R&D expense

7.2m10.2m

General and administrative expense

2.1m2.1m

Operating expense total

9.3m12.2m

EBIT

(9.3m)(12.2m)

Interest income

9.0k22.0k

Net Income

(13.6m)(12.2m)

Half Year

USDH1, 2016H1, 2017

R&D expense

5.1m6.3m

General and administrative expense

812.0k1.4m

Operating expense total

5.9m7.7m

EBIT

(5.9m)(7.7m)

Interest income

21.0k6.0k

Net Income

(5.9m)(7.7m)

Nightstar Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016

Cash

10.7m10.1m

Prepaid Expenses

3.1m4.1m

Current Assets

13.8m14.2m

PP&E

253.0k363.0k

Total Assets

14.1m14.6m

Accounts Payable

1.0m1.2m

Current Liabilities

3.0m5.6m

Total Liabilities

3.0m5.6m

Additional Paid-in Capital

32.0m43.5m

Retained Earnings

(20.1m)(32.3m)

Total Equity

11.1m9.0m

Financial Leverage

1.3 x1.6 x

Half Year

USDH1, 2017

Cash

69.6m

Prepaid Expenses

6.5m

Current Assets

76.1m

PP&E

342.0k

Total Assets

76.4m

Accounts Payable

3.0m

Current Liabilities

9.7m

Total Liabilities

9.7m

Common Stock

1.0k

Additional Paid-in Capital

107.1m

Retained Earnings

(40.0m)

Total Equity

66.7m

Financial Leverage

1.1 x

Nightstar Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016

Net Income

(13.6m)(12.2m)

Depreciation and Amortization

40.0k138.0k

Accounts Payable

384.0k419.0k

Cash From Operating Activities

(9.7m)(10.1m)

Purchases of PP&E

(289.0k)(306.0k)

Cash From Investing Activities

(289.0k)(306.0k)

Cash From Financing Activities

14.0m11.3m

Net Change in Cash

3.5m(554.0k)

Half Year

USDH1, 2016H1, 2017

Net Income

(5.9m)(7.7m)

Depreciation and Amortization

51.0k95.0k

Accounts Payable

91.0k1.7m

Cash From Operating Activities

(5.9m)(5.7m)

Purchases of PP&E

(186.0k)(55.0k)

Cash From Investing Activities

(186.0k)(55.0k)

Cash From Financing Activities

63.4m

Net Change in Cash

(6.7m)59.5m

Nightstar Therapeutics Ratios

USDY, 2017

Financial Leverage

1.1 x
Report incorrect company information